Arcturus Therapeutics Holdings (ARCT) Non-Current Deffered Revenue: 2018-2025
Historic Non-Current Deffered Revenue for Arcturus Therapeutics Holdings (ARCT) over the last 7 years, with Sep 2025 value amounting to $4.2 million.
- Arcturus Therapeutics Holdings' Non-Current Deffered Revenue fell 68.36% to $4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year decrease of 68.36%. This contributed to the annual value of $12.6 million for FY2024, which is 70.34% down from last year.
- Latest data reveals that Arcturus Therapeutics Holdings reported Non-Current Deffered Revenue of $4.2 million as of Q3 2025, which was down 51.88% from $8.8 million recorded in Q2 2025.
- Over the past 5 years, Arcturus Therapeutics Holdings' Non-Current Deffered Revenue peaked at $42.5 million during Q4 2023, and registered a low of $4.2 million during Q3 2025.
- Over the past 3 years, Arcturus Therapeutics Holdings' median Non-Current Deffered Revenue value was $12.6 million (recorded in 2024), while the average stood at $18.4 million.
- In the last 5 years, Arcturus Therapeutics Holdings' Non-Current Deffered Revenue spiked by 709.25% in 2023 and then tumbled by 70.34% in 2024.
- Arcturus Therapeutics Holdings' Non-Current Deffered Revenue (Quarterly) stood at $19.9 million in 2021, then grew by 0.70% to $20.1 million in 2022, then spiked by 111.73% to $42.5 million in 2023, then crashed by 70.34% to $12.6 million in 2024, then crashed by 68.36% to $4.2 million in 2025.
- Its Non-Current Deffered Revenue stands at $4.2 million for Q3 2025, versus $8.8 million for Q2 2025 and $9.6 million for Q1 2025.